Intravenous immunoglobulin: An emerging treatment for immune-mediated skin diseases

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 713-719

  Rütter, Anita ^a   Luger, Thomas A ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Atopic dermatitis; Dermatomyositis; IVIg; Kawasaki syndrome; Pemphigus; Pyoderma gangraenosum; Scleroderma; Skin disease; Systemic lupus erythematosus; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; SUCROSE;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BLOOD PRESSURE MEASUREMENT; CHILL; CHRONIC KIDNEY FAILURE; CHRONIC URTICARIA; CLINICAL STUDY; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; FLUSHING; GRAFT VERSUS HOST REACTION; HEADACHE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERIMMUNOGLOBULINEMIA E SYNDROME; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; LOW BACK PAIN; LUPUS ERYTHEMATOSUS; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYALGIA; NAUSEA; NEPHROSIS; PEMPHIGUS; PREMEDICATION; PYODERMA GANGRENOSUM; REVIEW; SCLERODERMA; SKIN DISEASE; TACHYCARDIA; THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VASOMOTOR DISORDER; VIRUS TRANSMISSION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SKIN DISEASES;

EID: 0036591178     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Hammarstrom L, Gardulf A, Hammarstrom V, Janson A, Lindberg K, Smith CI: Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol Rev (1994) 139:43-70.
2. Yap PL: Prevention of infection in patients with B cell defects: Focus on intravenous immunoglobulin. Clin Infect Dis (1993) 17 (Suppl 2):S372-S375.
3. Saint-Marc T, Touraine JL, Berra N: Beneficial effects of intravenous immunoglobulins in AIDS [letter]. Lancet (1992) 340:1347.
4. Dwyer JM: Manipulating the immune system with immune globulin. New Engl J Med (1992) 326:107-116.
5. Imbach P, Jungi TW: Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP). Blut (1983) 46:117-124.
6. Salama A, Mueller-Eckhardt C, Kiefel V: Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet (1983) 2:193-195.
7. Rossi F, Kazatchkine MD: Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 143:4104-4109.
8. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE: Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2:765-768.
9. Basta M: Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol (1996) 104(Suppl 1):21-25.
10. Zhuang Q, Mazer B: Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin. J Allergy Clin Immunol (2001) 108:229-234.
11. Andersson U, Bjork L, Skansen-Saphir U, Andersson J: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev (1994) 139:21-42.
12. Shimozato T, Iwata M, Kawada H, Tamura N: Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor α and interleukin-1 production. Immunology (1991) 72:497-501.
13. Campbell DE, Georgiou GM, Kemp AS: Pooled human immunoglobulin inhibits IL-4 but not IFN-γ or TNF-α secretion following in vitro stimulation of mononuclear cells with staphylococcal superantigen. Cytokine (1999) 11:359-365.
14. Arend WP, Leung DY: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev (1994) 139:71-78.
15. Ruetter A, Luger TA: High-dose intravenous immunoglobulins: An approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol (2001) 44:1010-1024.
16. Blasczyk R, Westhoff U, Grosse-Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations [see comments]. Lancet (1993) 341:789-790.
17. Ballow M: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol (1997) 100:151-157. Although the major component in IVIg is IgG, other minor components, such as solubilized lymphocyte surface membrane determinants and specific antibodies to lymphocyte surface molecules, may have important immunoregulatory effects.
18. Kekow J, Reinhold D, Pap T, Ansorge S: Intravenous immunoglobulins and transforming growth factor β [letter] [see comments]. Lancet (1998) 351:184-185.
19. Thivolet J: Pemphigus: Past, present and future. Dermatology (1994) 189(Suppl 2):26-29.
20. Stanley JR: Update: Structure and function of pemphigus vulgaris antigen. J Dermatol (1997) 24:741-743.
21. Harman KE, Black MM: High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: An evaluation of its use in 14 cases. Br J Dermatol (1999) 140:865-874.
22. Engineer L, Bhol KC, Ahmed AR: Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris [In Process Citation]. J Am Acad Dermatol (2000) 43:1049-1057.
23. Sami N, Qureshi A, Ahmed AR: Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur J Dermatol (2002) 12:174-178.
24. Ahmed AR: Intravenous immunoglobulin therapy in the treatment of patients with mephigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol (2001) 45:679-690. In patients with PV who do not respond to conventional immunosuppressants, IVIg appears to be an effective treatment alternative. Its early use is of significant benefit in patients who may experience life-threatening complications from immunosuppression. IVIg is effective as monotherapy.
25. Ahmed AR, Sami N: Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol (2002) 46:42-49.
26. Colonna L, Cianchini G, Frezzolini A, De Pita O, Di Lella G, Puddu P: Intravenous immunoglobulins for pemphigus vulgaris: Adjuvant or first choice therapy? [letter]. Br J Dermatol (1998) 138:1102-1103.
27. Humbert P, Derancourt C, Aubin F, Agache P: Effects of intravenous gamma-globulin in pemphigus [letter; comment]. J Am Acad Dermatol (1990) 22:326.
28. Wever S, Zillikens D, Brocker EB: Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy [letter]. Br J Dermatol (1996) 135:862-863.
29. Jenkins RE, Jones SA, Black MM: Conversion of pemphigoid gestationis to bullous pemphigoid - Two refractory cases highlighting this association. Br J Dermatol (1996) 135:595-598.
30. Enk AH, Knop J: [Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins]. Hautarzt (1998) 49:774-776.
31. Bewley AP, Keefe M: Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol (1996) 135:128-129.
32. Amagai M: Adhesion molecules. I: Keratinocyte-keratinocyte interactions; cadherins and pemphigus. J Invest Dermatol (1995) 104:146-152.
33. Ruetter GH, Sunderkötter C, Ruetter A, Biel K, Hildebrand A, Mohr C, Lugar TA, Kolde G. Intravenöse Immunglobuline, ein wirksames und gut verträgliches Additivum in der Behanding therapieresistenter Autoimmundermatosen. In: Tumoren und Haut, Jahrbuch der Dermatologie 1994/1995. Macher E, Kolde G, Bröcker EB (Eds), Biermann-Verlag, Germany (1994):275-288.
34. Ahmed AR: Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol (2001) 45:825-835. IVIg appears to be an effective alternative in treating patients with severe BP whose disease is unresponsive to conventional therapy. IVIg may be particularly useful, if treatment is begun early, in patients who are at risk of experiencing serious or potentially fatal side effects from conventional immunosuppressive therapy. After clinical control is achieved, IVIg therapy should be gradually withdrawn and not abruptly discontined.
35. Beckers RC, Brand A, Vermeer BJ, Boom BW: Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and billuous pemphigoid: Experience in six patients. Br J Dermatol (1995) 133:289-293.
36. Messer G, Sizmann N, Feucht H, Meurer M: High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris [letter]. Br J Dermatol (1995) 133:1014-1016.
37. Shimizu H, McDonald JN, Gunner DB, Black MM, Bhogal B, Leigh IM, Whitehead PC, Eady RA: Epidermolysis bullosa acquisita antigen and the carboxy terminus of type VII collagen have a common immunolocalization to anchoring fibrils and lamina densa of basement membrane. Br J Dermatol (1990) 122:577-585.
38. Mohr C, Sunderkotter C, Hildebrand A, Biel K, Ruetter A, Ruetter GH, Luger TA, Kolde G: Successful treatment of epidemolysis bullosa acquisita using intravenous immunologublins. Br J Dermatol (1995) 132:824-826.
39. Kofler H, Wambacher-Gasser B, Topar G, Weinlich G, Schuler G, Hintner H, Romani N, Fritsch P: Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol (1997) 36:331-335.
40. Hern S, Harman K, Bhogal BS, Black MM: A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol (1998) 23:185-188.
41. Engineer L, Ahmed AR: Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: Analysis of current data. J Am Acad Dermatol (2001) 44:83-88.
42. Kroiss MM, Vogt T, Landthaler M, Stolz W: High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol (2000) 142:582.
43. Khan IU, Bhol KC, Ahmed AR: Linear IgA bullous dermatosis in a patient with chronic renal failure: Response to intravenous immunoglobulin therapy. J Am Acad Dermatol (1999) 40:485-488.
44. Dalakas MC: Polymyositis, dermatomyositis and inclusion-body myositis [see comments]. New Engl J Med (1991) 325:1487-1498.
45. Jolles S, Hughes J, Whittaker S: Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol (1998) 134:80-86.
46. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Degennes C, Ziza JM, Du LT, Godeau P: Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis. An open trial in 15 patients. Presse Med (1991) 20:244-249.
47. Collet E, Dalac S, Maerens B, Coutois JM, Izac M, Lambert D: Juvenile dermatomyositis: Treatment with intravenous gammaglobulin. Br J Dermatol (1994) 130:231-234.
48. Furuya Y, Takahashi T, Hamamoto H, Nishimura M, Kawakami Y: High-dose immunoglobulin therapy for a patient with d ermatomyositis. Intern Med (1998) 37:642-645.
49. Sabroe RA, Wallington TB, Kennedy CT: Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Clin Exp Dermatol (1995) 20:164-167.
50. Schmidt K, Westenberger-Treumann M, Stadler R: [High dosage intravenous gamma globulin therapy in juvenile dermatomyositis]. Hautarzt (1994) 45:854-857.
51. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC: Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol (2000) 94:99-104.
52. Dalakas MC: Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology (1998) 51:S37-S45. High-dose IVIg has been tried in controlled clinical trials in patients with DM and IBM but not with PM. In patients with DM that is resistant or partially responsive to coventional therapies, IVIg was very effective. The treated patients experienced dramatic improvement not only in muscle strength but also of their skin rash.
53. Peake MF, Perkins P, Elston DM, Older SA, Vinson RP: Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis (1998) 62:89-93.
54. Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B: High dose intravenous immunoglobulin (IVIG) in dermatomyositis: Clinical responses and effect on sL-2R levels. Eur J Dermatol (2000) 10:29-35. IVIg is effective in selected dermatomyositis patients. sIL-2R serum levels appear to be useful predictors of IVIg-induced treatment response and disease activity.
55. Scofield RH, Farris AD, Horsfall AC, Harley JB: Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins. Arthritis Rheum (1999) 42:199-209.
56. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y: Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: Report of 2 cases. J Rheumatol (1993) 20:495-498.
57. Schroeder JO, Zeuner RA, Euler HH, Loffler H: High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol (1996) 23:71-75. In this uncontrolled study, IVIg had temporary beneficial effects in mildly to moderately active SLE.
58. Pirner K, Rubbert A, Burmester GR, Kalden JR, Manger B: [Intravenous administration of immunoglobulins in systemic lupus erythematosus: Review of the literature and initial clinical experiences]. Infusionsther Transfusionsmed (1993) 20(Suppl 1):131-135.
59. Becker BN, Fuchs H, Hakim R: Intravenous immune globulin in the treatment of patients with systemic lupus erythematosus and end-stage renal disease. J Am Soc Nephrol (1995) 5:1746-1750.
60. Akashi K, Nagasawa K, Mayumi T, Yokota E, Oochi N, Kusaba T: Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol (1990) 17:375-379.
61. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R: Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol (1994) 12:163-168.
62. Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y: Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol (1999) 18:170-173.
63. Sturfelt G, Mousa F, Jonsson H, Nived O, Thysell H, Wollheim F: Recurrent cerebral infarction and the antiphospholipid syndrome: Effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis (1990) 49:939-941.
64. Genereau T, Chosidow O, Danel C, Cherin P, Herson S: High-dose intravenous immunoglobulin in cutaneous lupus erythematosus [letter]. Arch Dermatol (1999) 135:1124-1125.
65. Haustein UF, Anderegg U: Pathophysiology of scleroderma: An update. J Eur Acad Dermatol Venereol (1998) 11:1-8.
66. Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, De Prost Y: Efficacy of intravenous immunoglobulins in sclerodermatomyositis [letter]. Br J Dermatol (1990) 123:545-546.
67. Ruetter A, Luger TA: Intravenöse Immunoglobuline in der Behandlung von Autoimmuerkrankungen der Haut. In: Immunregulation mit iv Immunglobulinen bei Autoimmunerkrankungen und Infektionen. Sibrowski W, Marzusch K (Eds), Pmi-Verlagsgruppe, Frankfurt, Germany (1997):70-91.
68. Wollina U, Looks A, Schneider R, Maak B: Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy [letter]. Clin Exp Dermatol (1998) 23:292-293.
69. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs [see comments]. New Engl J Med (1994) 331:1272-1285.
70. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 282:490-493. In a pilot study, ten consecutive individuals with clinically and histologically confirmed TEN were treated with IVIg; Disease progression was rapidly reversed and the outcome was favorable in all cases. Thus, Fas-FasL interactions are directly involved in the epidermal necrolysis of TEN, and IVIg may be an effective treatment.
71. Magina S, Lisboa C, Goncalves E, Conceicao E, Leal V, Mesquita-Guimaraes J: A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol (2000) 142:191-192.
72. Stella M, Cassano P, Bollero D, Clemente A, Giorio G: Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: Our experience. Dermatology (2001) 203:45-49.
73. Van Joost T, Heule F, Korstanje M, Van Den Broek MJ, Stenveld HJ, Van Vloten WA: Cyclosporin in atopic dermatitis: A multicentre placebo-controlled study. Br J Dermatol (1994) 130:634-640.
74. Hanifin JM: Assembling the puzzle pieces in atopic inflammation [editorial; comment]. Arch Dermatol (1996) 132:1230-1232.
75. Brehler R, Hildebrand A, Luger TA: Recent developments in the treatment of atopic eczema. J Am Acad Dermatol (1997) 36:983-994.
76. Kimata H: High dose gammaglobulin treament for atopic dermatitis. Arch Dis Child (1994) 70:335-336.
77. Gelfand EW, Landwehr LP, Esterl B, Mazer B: Intravenous immune globulin: An alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol (1996) 104(Suppl 1):61-66. IVIg may be a potent alternative in the treatment of severe, steroid-dependent allergic disorders, reducing steroid dependency.
78. Jolles S, Hughes J, Rustin M: Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. J Am Acad Dermatol (1999) 40:121-123.
79. Davis SD, Schaller J, Wedgwood RJ: Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet (1966) 1:1013-1015.
80. Kimata H: High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol (1995) 95:771-774.
81. Rousset F, Robert J, Andrary M, Bonnin JP, Souillet G, Chretien I, Briere F, Pene J, De Vries JE: Shifts in interleukin-4 and interferon-γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol (1991) 87:58-69.
82. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM: Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol (1996) 106:1001-1006.
83. Fiebiger E, Hammerschmid F, Stingl G, Maurer D: Anti-FcεRIα autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest (1998) 101:243-251.
84. Ellis MH: Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol (1998) 102:876-877.
85. Kessel A, Toubi E, Golan D: [Chronic urticaria - Update]. Harefuah (1998) 134:49-52.
86. O'Donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N, Barlow RJ, Winkelmann RK, Greaves MW: Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dematol (1998) 138:101-106. IVIg represents a novel therapeutic option in selected patients with recalcitrant autoimmune chronic urticaria associated with histamine-releasing autoantibodies.
87. Callen JP: Pyoderma gangrenosum and related disorders. Adv Dermatol (1989) 4:51-65.
88. Callen JP, Case JD, Sager D: Chlorambucil - An effective corticosteroid-sparing therapy for pyoderma gangrenosum. J Am Acad Dermatol (1989) 21:515-519.
89. Gupta AK, Shear NH, Sauder DN: Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol (1995) 32:140-142.
90. Dirschka T, Kastner U, Behrens S, Altmeyer P: Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol (1998) 39:789-790.
91. Gleichmann US, Otte HG, Korfer R, Stadler R: [Post-traumatic pyoderma gangrenosum: Combination therapy with intravenous immunoglobulins and systemic corticosteroids]. Hautarzt (1999) 50:879-883.
92. Huff JC, Weston WL, Tonnesen MG: Erythema multiforme: A critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol (1983) 8:763-775.
93. Schofield JK, Tatnall FM, Leigh IM: Recurrent erythema multiforme: Clinical features and treatment in a large series of patients. Br J Dermatol (1993) 128:542-545.
94. Andolina M, Giorgi R, Maximova N, Comar M: [Intravenous immunoglobulins in bone marrow transplantation]. Pediatr Med Chir (1993) 15:347-348.
95. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C et al: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant (1996) 2:44-53.
96. Leung DY, Schlievert PM, Meissner HC: The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum (1998) 41:1538-1547.
97. Rowley AH, Shulman ST: Kawasaki syndrome. Clin Microbiol Rev (1998) 11:405-414.
98. Leung DY: The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases. Clin Rev Allergy (1992) 10:93-104.
99. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS: Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease [see comments]. Lancet (1989) 2:1298-1302.
100. Duhem C, Dicato MA, Ries F: Side-effects of intravenous immune globulins. Clin Exp Immunol (1994) 97(Suppl 1):79-83. This article summarizes most of the adverse experiences with IVIg reported in the literature since its introduction into clinical practice almost 15 years ago.
101. Reinhart WH, Berchtold PE: Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet (1992) 339:662-664.
102. Ahsan N, Wiegand LA, Abendroth CS, Manning EC: Acute renal failure following immunoglobulin therapy. Am J Nephrol (1996) 16:532-536.
103. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol (1993) 50:137-139.
104. Thomas MJ, Misbah SA, Chapel HM, Jones M, Erlington G, Newsom-Davis J: Hemolysis after high-dose intravenous Ig [letter]. Blood (1993) 82:3789.